1. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia 
M. Lafaurie, J. Lapalu, E. Raffoux, B. Breton, C. Lacroix, G. Socié, R. Porcher, P. Ribaud, S. Touratier, J.-M. Molina 
Clinical Microbiology and Infection 
Volume 16, Issue 8, Pages (August 2010)
DOI: /j x
Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions

2. FIG. 1
Empirical antifungal therapies (EAFT) and outcome during 56 episodes of febrile neutropenia after chemotherapy among 49 patients. *Switch from liposomal amphotericin B (AmB) to caspofungin (n = 6) because of toxicity (renal insufficiency, n = 4) or side effects (infusion related chills, n = 2). **Suspected invasive aspergillosis (n = 2), hospital discharge (n = 2).
Clinical Microbiology and Infection  , DOI: ( /j x)
Copyright © 2010 European Society of Clinical Infectious Diseases Terms and Conditions